Literature DB >> 26102075

Large-scale production of pharmaceutical proteins in plant cell culture-the Protalix experience.

Yoram Tekoah1, Avidor Shulman1, Tali Kizhner1, Ilya Ruderfer1, Liat Fux1, Yakir Nataf1, Daniel Bartfeld1, Tami Ariel1, Svetlana Gingis-Velitski1, Uri Hanania1, Yoseph Shaaltiel1.   

Abstract

Protalix Biotherapeutics develops recombinant human proteins and produces them in plant cell culture. Taliglucerase alfa has been the first biotherapeutic expressed in plant cells to be approved by regulatory authorities around the world. Other therapeutic proteins are being developed and are currently at various stages of the pipeline. This review summarizes the major milestones reached by Protalix Biotherapeutics to enable the development of these biotherapeutics, including platform establishment, cell line selection, manufacturing process and good manufacturing practice principles to consider for the process. Examples of the various products currently being developed are also presented.
© 2015 Society for Experimental Biology, Association of Applied Biologists and John Wiley & Sons Ltd.

Entities:  

Keywords:  Protalix Biotherapeutics; enzyme replacement therapy; molecular farming; oral delivery; plant cell culture; β-glucocerebrosidase

Mesh：

Substances：

Year:  2015        PMID： 26102075     DOI： 10.1111/pbi.12428

Source DB:  PubMed          Journal:  Plant Biotechnol J        ISSN： 1467-7644            Impact factor:   9.803


  43 in total

Review 1.  Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development.

Authors:  Nagesh K Tripathi; Ambuj Shrivastava
Journal:  Front Bioeng Biotechnol       Date:  2019-12-20

2.  Plant specific N-glycans do not have proven adverse effects in humans.

Authors:  Yoseph Shaaltiel; Yoram Tekoah
Journal:  Nat Biotechnol       Date:  2016-07-12       Impact factor: 54.908

Review 3.  Vacuolar deposition of recombinant proteins in plant vegetative organs as a strategy to increase yields.

Authors:  Vanesa Soledad Marin Viegas; Carolina Gabriela Ocampo; Silvana Petruccelli
Journal:  Bioengineered       Date:  2016-09-20       Impact factor: 3.269

Review 4.  Current advances and future prospects in production of recombinant insulin and other proteins to treat diabetes mellitus.

Authors:  Sapna Bhoria; Jyoti Yadav; Honey Yadav; Darshna Chaudhary; Ranjana Jaiwal; Pawan K Jaiwal
Journal:  Biotechnol Lett       Date:  2022-04-17       Impact factor: 2.461

Review 5.  Immunogenicity Risk Assessment for an Engineered Human Cytokine Analogue Expressed in Different Cell Substrates.

Authors:  Paul Chamberlain; Bonita Rup
Journal:  AAPS J       Date:  2020-04-14       Impact factor: 4.009

6.  Advances in molecular farming: key technologies, scaled up production and lead targets.

Authors:  Henry Daniell; Stephen J Streatfield; Edward P Rybicki
Journal:  Plant Biotechnol J       Date:  2015-10       Impact factor: 9.803

Review 7.  New drugs for the treatment of Anderson-Fabry disease.

Authors:  Sandro Feriozzi; Derralynn A Hughes
Journal:  J Nephrol       Date:  2020-03-20       Impact factor: 3.902

8.  CRISPR/Cas9-mediated gfp gene inactivation in Arabidopsis suspension cells.

Authors:  Natalya V Permyakova; Yury V Sidorchuk; Tatyana V Marenkova; Sofya A Khozeeva; Vitaly V Kuznetsov; Alla A Zagorskaya; Sergei M Rozov; Elena V Deineko
Journal:  Mol Biol Rep       Date:  2019-08-07       Impact factor: 2.316

Review 9.  Quality Control and Downstream Processing of Therapeutic Enzymes.

Authors:  David Gervais
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

10.  Dramatic secretion of recombinant protein expressed in tobacco cells with a designer glycopeptide tag is highly impacted by medium composition.

Authors:  Ningning Zhang; Maureen Dolan; Di Wu; Gregory C Phillips; Jianfeng Xu
Journal:  Plant Cell Rep       Date:  2016-09-08       Impact factor: 4.570
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.